Cargando…

P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

Detalles Bibliográficos
Autores principales:	Zheng, Zhong, Zhang, Huilai, Zhou, Keshu, Zhou, Hui, Zhang, LI, LI, Caixia, Zhou, Min, Qian, Wenbin, LI, Zhiming, Zhang, Qingyuan, Cheng, Ying, Peng, Liu, LI, Zhenyu, Su, Liping, LI, Fei, Sun, Xiuhua, Wang, Jingwen, Gao, Yuhuan, Zhao, Xielan, LI, Kunyan, Ding, Kaiyang, Zhu, Zunmin, Wang, Ying, Jing, Hongmei, Xu, Xiaohong, Wang, Xin, Sun, Zimin, Gao, Da, Zhao, Wei-LI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430982/ http://dx.doi.org/10.1097/01.HS9.0000971292.12638.60

Ejemplares similares

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases
por: Li, Yang, et al.
Publicado: (2021)

Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Analysis and Follow up of Endoscopy Results in 1099 Patients with Terminal Ileum Lesions
por: Zhong, Qinglian, et al.
Publicado: (2020)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

Fish welfare during slaughter: the European Council Regulation 1099/09 application
por: Mercogliano, Raffaelina, et al.
Publicado: (2023)

PyMT-1099, a versatile murine cell model for EMT in breast cancer
por: Saxena, Meera, et al.
Publicado: (2018)

1099. The Correlation Between Antimicrobial Utilization and Resistance in a Medical Intensive Care Unit
por: Ahern, John W, et al.
Publicado: (2019)

Primary pulmonary Hodgkin's lymphoma mimicking rheumatoid arthritis‐associated organizing pneumonia: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
por: Song, Yuqin, et al.
Publicado: (2022)

1099. CMV PCR Agreement between Blood and Dried Blood Spots in Infants with Congenital Cytomegalovirus Infection
por: Kim, Juhyeong, et al.
Publicado: (2023)

1099. Opportunistic Infections Among Long Term Survivors of Kidney Transplantation: Defining Risk Factors
por: Cheung, Harry, et al.
Publicado: (2020)

SG-APSIC1099: Scoping review of cleaning of high-touch surfaces (HTSs) in inpatient wards
por: Loo, Liang Hui, et al.
Publicado: (2023)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study
por: Zhang, Wei, et al.
Publicado: (2021)

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
por: Hu, Shaoxuan, et al.
Publicado: (2018)

Efficacy, safety and bioequivalence of the human‐derived B‐domain‐deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients
por: Xi, Yaming, et al.
Publicado: (2022)

NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization
por: Narang, Sonali, et al.
Publicado: (2023)

Author Correction: PyMT-1099, a versatile murine cell model for EMT in breast cancer
por: Saxena, Meera, et al.
Publicado: (2020)

Research on Mechanical Properties and Damage Evolution of Pultruded Sheet for Wind Turbine Blades
por: He, Ying, et al.
Publicado: (2022)

Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study
por: Zha, Jie, et al.
Publicado: (2023)

P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.
por: Zhi-Ming, LI, et al.
Publicado: (2023)

1099. Antibiotic Prescriptions for Acute Gastroenteritis during Office and Emergency Department Visits–United States, 2006–2015
por: Collins, Jennifer P, et al.
Publicado: (2018)

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies
por: Han, Lu, et al.
Publicado: (2021)

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
por: Naing, Aung, et al.
Publicado: (2022)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
por: Trněný, Marek, et al.
Publicado: (2023)

F1099L-CFTR (c.3297C>G) has Impaired Channel Function and Associates with Mild Disease Phenotypes in Two Pediatric Patients
por: Zhang, Xiaoying, et al.
Publicado: (2021)

Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells
por: Li, Qingyong, et al.
Publicado: (2011)

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Huilai, et al.
Publicado: (2023)

Council Regulation (EC) No. 1099/2009: State of the Art and Its Application in a Local Health Unit in Piedmont, Italy
por: Paolucci, Ginevra, et al.
Publicado: (2015)

P1167: TREATMENT OF RELAPSED/REFRACTORY HGBCL WITH MYC REARRANGEMENT: A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF PC-002(SEPB)，A FIRST-IN-CLASS INHIBITOR OF DEUBIQUITINASES TARGETING MYC DEGRADATION
por: Yoon, Sung-Soo, et al.
Publicado: (2023)

Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

High Glucose Decreases Expression and Activity of p-glycoprotein in Cultured Human Retinal Pigment Epithelium Possibly through iNOS Induction
por: Zhang, Yuehong, et al.
Publicado: (2012)

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
por: Wang, Tingyu, et al.
Publicado: (2023)

Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study
por: Jiang, Bo, et al.
Publicado: (2020)

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY
por: Yacoub, A., et al.
Publicado: (2022)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Publicado: (2022)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

The application of GPR to the detection of soil wetted bodies formed by drip irrigation
por: Peng, Gao, et al.
Publicado: (2020)

Preparation and Physicochemical Properties of 10-Hydroxycamptothecin (HCPT) Nanoparticles by Supercritical Antisolvent (SAS) Process
por: Zhao, Xiuhua, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c8535b0kokmahph11oe2gg246b